INTRODUCTION
Group B streptococcus (GBS) infections are the leading bacterial cause of disease among newborns in the United States. In 1993, the annual cost of caring for newborns with GBS was an estimated $294 million. 1 During the 1980s several studies identified intrapartum antimicrobial prophylaxis as an effective strategy for prevention of early-onset GBS infections. 2, 3 In 1996, the Centers for Disease Control (CDC), in conjunction with American College of Obstetricians and Gynecologists (ACOG) and American Academy of Pediatrics (AAP), issued consensus guidelines for identifying candidates for treatment with intrapartum antimicrobial prophylaxis. 4 The consensus guidelines recommend that all prenatal care providers and hospitals adopt a policy for GBS prevention using either the 1996 consensus guidelines' strategy of screening at 35 to 37 weeks' gestation or a risk-based strategy applied to patients in labor. According to the screening-based strategy, all women identified as GBS carriers at 35 to 37 weeks' gestation, and all women with premature onset of labor or preterm membrane rupture, should be offered intrapartum antimicrobial prophylaxis. According to the risk-based strategy, all women who develop one or more risk conditions at the time of labor or membrane rupture should receive intrapartum antibiotics.
OBJECTIVE:
To compare the Center for Disease Control consensus guidelines' screeningbased strategy to a risk -based strategy as regards the incidence of earlyonset group B streptococcus ( GBS ) infection among term infants.
STUDY DESIGN:
A cohort of university hospital prenatal clinic mother ± infant pairs who were screened for GBS at 35 to 37 weeks' gestation were compared to a matched control group of unscreened mother ± infant pairs from the outreach satellite prenatal clinics who delivered at the same institution during the same time period. GBS screening was carried out with rectovaginal cultures plated on selective media. GBS -positive women received antimicrobial prophylaxis in labor whereas women of unknown GBS status were only treated intrapartum if they had a risk factor for GBS infection. Principal outcome variables included incidence of cases of neonatal early -onset GBS sepsis ( blood, urine, or cerebrospinal fluid positive for GBS ) , incidence of cases of strongly suspected GBS sepsis ( culture negative ) , and incidence of neonatal sepsis with non -GBS organisms.
RESULTS:
There were 3164 screened mother ± infant pairs who were compared to 2684 unscreened pairs. The incidence of GBS carriage was 13.3%. A random sample of 420 screened women were compared to a matched sample of 407 women of unknown GBS carrier status for characterization of demographics and risk factors. No cases of documented GBS sepsis occurred in the infants of the screened women, but four cases occurred among the infants of the women who did not undergo screening ( incidence 1.5 / 1000 ) ( p = 0.04 ) , only one of whom had a risk factor for GBS infection. Cases of suspected but culture negative sepsis were not more common in the screened population when compared to the unscreened. There was one case of Escherichia coli sepsis in an infant of a mother in the unscreened group.
CONCLUSIONS:
GBS screening at 35 to 37 weeks, with intrapartum antimicrobial prophylaxis of carriers, decreased the incidence of neonatal early -onset GBS sepsis and appears to have advantages over treatment based on risk factors alone in term infants. 
Original Article
Adoption of GBS prevention policies has resulted in lower incidences of early-onset GBS disease. 5 However, a number of issues remain unresolved. Which strategy is most efficacious, which is most cost-effective, and which is logistically best suited for clinical implementation, remain important questions. Another critical area of speculation has been whether intrapartum antimicrobial prophylaxis will interfere with neonatal bacterial culture results, thus decreasing the incidence of laboratory-confirmed GBS infections but increasing the incidence of culture-negative sepsis. Another area of concern is whether increasing use of intrapartum antimicrobials will lead to increasing rates of neonatal infections caused by non-GBS pathogens, and whether there will emerge an increasing proportion of antimicrobial resistance among these pathogens.
The objective of the current study is to compare the consensus guidelines' screening-based strategy and the risk-based strategy as regards the incidence of early-onset GBS infections among term infants born at our institution. We also intend to compare the two protocols as regards the incidence of culture-negative sepsis, and the incidence of sepsis due to non-GBS bacterial pathogens, among these same infants.
STUDY DESIGN
We conducted a retrospective cohort study including all women who were delivered of live term infants at the University of New Mexico Hospital between October 1, 1994 and June 30, 1996. The Human Research Review Committee of the University of New Mexico Health Sciences Center approved the study before its inception. Before the publication of the CDC consensus conference document of March 26, 1995, we had instituted an investigational protocol for GBS screening of the prenatal patients attending the University of New Mexico Hospital Women's Health Clinic. We attempted to obtain GBS cultures on pregnant women at 36 weeks' gestation (logistically this actually occurred between 35 and 37 weeks' gestation) and we offered intrapartum antibiotics to all who were found to have GBS colonization. When colonization status was unknown, antimicrobial prophylaxis was provided on the basis of risk factors. The women with known GBS status were compared to a control population of women delivering at our hospital whose prenatal care had been obtained at outlying satellite clinics where GBS screening had not been implemented. These women were given chemoprophylaxis in labor on the basis of risk factors. Women and their infants with preterm ( 35 weeks) labor, or preterm ( 35 weeks) premature rupture of membranes, were excluded from the study. Infants of women who had been transported to our facility after delivery were also excluded from the analysis.
At 35 to 37 weeks' gestation, both lower vaginal and rectal swabs (two swabs) were collected and combined in transport medium, inoculated, and incubated in selective Todd-Hewitt broth for 16 to 24 hours, and then subcultured onto nonselective 5% sheep blood agar. Culture results are entered daily in the microbiology laboratory database as well as being transmitted to one of us (G. J. G.) on a daily basis. Intrapartum chemoprophylaxis was given to all GBSpositive women and to term patients with the following risk factors: maternal fever (!388C) in labor, prolonged (!18 hours) rupture of membranes, or a history of a prior GBS affected infant. Before March, 1995, patients received ampicillin 2 g intravenously every 6 hours while in labor, but after that date, patients received an initial intravenous dose of 5.0 million units of aqueous penicillin G followed by 2.5 million units intravenously every four hours until delivery. Patients with a history of penicillin allergy were treated with clindamycin 900 mg intravenously every 8 hours while in labor.
Maternal outcome data included the incidence of concomitant sexually transmitted diseases (chlamydia, gonorrhea, and syphilis) as well as other maternal infectious complications. We noted the incidence of intrapartum chorioamnionitis (defined as temperature !388C in labor accompanied by at least one of the following: maternal or fetal tachycardia, uterine tenderness, or malodorous amniorrhea), and postpartum endometritis (defined as temperature !388C during the first 72 hours postpartum accompanied by uterine tenderness and/or malodorous lochia). Data was obtained from the obstetric data base as well as by individual chart review. Data entry occurs daily and is ongoing. It includes demographic characteristics, source of prenatal care, antenatal conditions, and intrapartum complications.
Early-onset neonatal sepsis was determined by prospectively defining three groups of infants. 6 Group 1 comprised infants in whom GBS was isolated from a normally sterile central site (blood, cerebrospinal fluid, or urine obtained by suprapubic aspiration) within the first 7 days of life. Group 2 included all infants with a negative blood culture but in whom the pediatric staff maintained a strong clinical suspicion of sepsis and who were maintained on intravenous antibiotics for 7 to 10 days. Strongly suspected sepsis included presence of one or more of the following signs and/or symptoms: (1) pneumonia (defined as presence of respiratory distress, including a respiratory rate !60, intercostal retractions, persistent oxygen requirement, and a pediatric radiologic diagnosis of pulmonary infiltrates consistent with pneumonitis), (2) ratio of immature to total neutrophils !0.20, (3) neutropenia with an absolute neutrophil count 1.5Â10 9 /l, (4) persistent apneic and bradycardic episodes refractory to all treatment except mechanical ventilation, (5) hyperglycemia (!120 mg/dl) or hypoglycemia ( 30 mg/dl fasting) concurrent with temperature instability, and (6) thrombocytopenia (platelet count 100,000/mm 3 ) in the infant of a mother without signs of preeclampsia. Group 3 comprised infants with low probability sepsis, defined as those infants considered possibly at risk for GBS sepsis and who were observed on antibiotics for 48 to 72 hours or until culture results were known to be negative. We also examined the total cohort for the incidence of cases of earlyonset neonatal sepsis that were documented by central cultures to be secondary to non-GBS organisms. Cases were found by querying the neonatology database for the final diagnosis of sepsis on a daily basis to assure our obtaining all cases of GBS sepsis. Data collection and entry occurs daily and is ongoing. It includes patient demographic Gilson et al.
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In an effort to determine whether the protocol would be feasible to implement and whether there was adherence to the protocol, we examined several parameters. These included the percent of known GBS-positive women appropriately administered intrapartum antimicrobial prophylaxis, the mean number of doses administered before birth, the percent of women receiving antibiotics at least 4 hours before birth, and whether any adverse reactions to the drug occurred. This data was determined from the pharmacy database by verifying the amount of ampicillin, penicillin G, and clindamycin dispensed to patients on the Labor and Delivery unit per day and at what time, and correlating this data with patient records to be sure only study cases were included.
Demographic variables and risk factors of women who were screened for GBS were compared to those of women of undetermined GBS status using two-tailed Student's t-tests for the continuous variables, Fisher's exact test for the binary frequency data, and the Wilcoxon rank sum test for the nonparametric data. Statistical analysis was performed on SAS (SAS Institute, Cary, NC) and StatXact-Turbo (CYTEL Software Corporation, Cambridge, MA) software. A p value of <0.05 was considered significant.
RESULTS
During the study period from October 1, 1994 to June 30, 1996, 2563 pregnant women in the University Hospital Women's Health Center's prenatal clinics' population were screened for GBS carriage at 35 to 37 weeks' gestation. This represented 81% of the eligible population of 3164 women. Intent to treat analysis for the outcome of earlyonset neonatal GBS sepsis in this cohort was utilized. A total of 340 women were found to be GBS positive, a prevalence of 13.3%. Another 2684 women whose prenatal care had been obtained at outlying satellite clinics, where GBS screening was not provided, comprised the control population. For purposes of this review a sample was selected from these two populations for characterization and comparison of demographics and risk factors. We intended to analyze 500 randomly chosen charts (i.e., first available charts) from the group of women screened for GBS and their infants, and 500 first available charts of the GBS unknown (control) mother±infant pairs for these variables. Of the 1000 mother±infant sample size sought for the study period, 827 maternal and 827 matched infant charts containing complete outcome data were available for analysis, of which 420 were GBS screened mother±infant pairs and 407 were GBS status unknown pairs.
In the sample analyzed there was no clinically significant difference between the groups with regards to the demographic variables of maternal age, gestational age at delivery, parity, or infant weights. There was likewise no significant difference between the groups in length of rupture of membranes, incidence of chorioamnionitis or endometritis, or prevalence of chlamydia, gonorrhea, or syphilis (Table 1) .
For the population in question there were no cases of early-onset neonatal GBS sepsis in the infants of the women who had undergone GBS screening (0/3164). There were four cases of central cultures positive for GBS in the infants of the mothers of unknown GBS carrier status (4/2684), an incidence of 1.5/1,000 (p=0.04). Three infants had positive blood cultures and one had a positive transabdominally collected urine culture. All were symptomatic and were treated with 7 to 10 days of intravenous antibiotics. Three of these infants were born to mothers with no risk factors. One mother, who was identified as being at risk secondary to developing fever in advanced labor, was treated with one dose of intravenous clindamycin less than 4 hours before being delivered by cesarean section. There was one case of documented E. coli sepsis in an infant in the unscreened group, but no cases of sepsis secondary to gramnegative organisms occurred in the screened groups. There was no significant difference among the three groups in the number of infants diagnosed with strongly suspected sepsis who underwent 7 to 10 days of therapeutic antibiotics, or in the number of infants GBS screened ( n = 420 ) GBS unscreened ( n = 407 )
Overall days LOS 2.3 3.9 2.0 2.0 Culture ( + ) for GBS days LOS ± ( n =0 ) 9.8 5.5* ( n =4 ) Strongly suspected sepsis days LOS 7.0 1.7 ( n =6 ) 7.2 1.5 ( n =11 ) Low probability sepsis days LOS 3.3 0.9 ( n =6 ) 3.6 0.7 ( n =9 ) *p < 0.001 for LOS compared to the screened group.
diagnosed with low probability sepsis and were treated for 48 to 72 hours. Likewise, length of stay was not different between groups, except for those infants in the control group with documented GBS sepsis ( Table 2) . Adherence to the protocol was assessed by evaluating the records of the GBS-positive mothers. Complete information was obtained from the charts of 180 of 216 GBS-positive women. Of the culture positive women analyzed, 130 (72%), were appropriately treated with at least one dose of antibiotic. Eighty-six women (48%) received antimicrobial prophylaxis at least 4 hours before delivery, another 24% of these women were treated, but at less than 4 hours before delivery, and 28% did not receive treatment at all. The mean number of doses given before birth was 2.11.4 and the median dose was 1 (range 1 to 6). No cases of adverse reactions to antibiotics were noted.
DISCUSSION
Maternal GBS carriage remains an important cause of early-onset neonatal sepsis, but controversy persists as regards the optimal strategy for prevention. Before, and continuing after, the publication of the CDC consensus guidelines for GBS prevention, the current study independently attempted to address this issue by investigating outcomes in a university clinic population screened at 35 to 37 weeks' gestation, and comparing them to outcomes in an unscreened satellite clinic population delivering at the same institution during the same time period. Our results demonstrate a decreased incidence of early-onset neonatal GBS sepsis in the infants of the screened women receiving intrapartum antimicrobial prophylaxis when compared to the infants of the unscreened women treated on the basis of risk factors (p=0.04). In the unscreened cohort there were four neonates with proven GBS sepsis, only one of whose mothers had a risk factor. This data agrees with the results of Hafner et al., 7 who observed a five-fold reduction in rates of early-onset neonatal GBS sepsis over two time periods during which a universal screening-based strategy supplanted a risk-based strategy. These results, however, were not found by Locksmith et al., 8 who were unable to document statistically significant improvement in neonatal outcomes under the universal screening protocol compared to the risk-based protocol implemented at different time periods. The results are consistent with the conclusions of the decision analysis of Rouse et al. 9 To our knowledge the current study is the first to compare a cohort of patients managed under the two protocols concomitantly. In view of the low incidence of the principal outcome variable, early-onset neonatal GBS sepsis, we acknowledge that the sample size studied is relatively small. Nevertheless, we are confident we have identified all cases of early-onset neonatal sepsis occurring in the 5848 women delivering term infants in our institution during this time period. We also feel that we have obtained a representative sample of women in both the screened and unscreened groups to be able to meaningfully compare them.
Concern about changes in microbial flora and the emergence of sepsis due to non-GBS, gram-negative organisms is an important argument against the intrapartum treatment of all GBS carriers. 10 However, among the 920 mother±infant pairs evaluated in this study, there was only one documented case of neonatal E. coli sepsis, which occurred in an infant of a mother in the risk-based strategy group. Because antimicrobial susceptibility testing of GBS isolates was not routine policy at our institution during the study period, and all infants with suspected sepsis were treated with both ampicillin and gentamicin, we are unable to make any observations about the emergence of antibiotic resistance among our GBS isolates. Because of this theoretic concern, however, we changed our prophylactic antibiotic protocol to the use of penicillin rather than ampicillin 6 months into the study. As noted by others, 11, 12 this remains an important clinical issue deserving of ongoing surveillance.
An increase in the incidence of pediatric septic work-ups has been cited as a``hidden cost'' of the CDC screening-based strategy. 13 Due to the nonspecific signs and symptoms with which septic infants may present, clinicians may choose a conservative strategy in managing suspect neonates.
14 Likewise, the CDC guidelines 4 recommend that pediatricians observe asymptomatic infants for at least 48 hours if their mothers receive more than 4 hours of intrapartum antimicrobial prophylaxis, and that they obtain a complete blood count and a blood culture in addition to observation if less than 4 hours of antibiotics were administered. On the basis of investigation carried out in our institution, we elected to follow a clinical strategy that observed or treated infants for suspected sepsis on the basis of defined clinical characteristics. 6 Following this strategy, the incidence of both strongly suspected sepsis and low probability sepsis in this population of term infants was low. Length of stay was likewise not significantly different between groups (Table 2) . Actual costs were not calculated in this study, but the low incidence of extended stays in the infants in the screening-based strategy groups are unlikely to elevate total costs significantly.
We found that compliance with the protocol was fair. Only 48% of patients who were candidates for antimicrobial prophylaxis received them appropriately in a timely fashion within 4 hours of delivery. Reasons for failure to provide prophylaxis included presentation in advanced labor, provider error in failing to note a positive culture report, and culture results not being available at the time the patient presented in labor. The latter situation was the least common reason antibiotics were not administered, as computerized laboratory results are readily available in the labor and delivery area. These results are similar to other investigations of compliance with the CDC protocols. 15, 16 An investigation of reasons for failure to adhere to the risk-based protocol in the unscreened group of women was not specifically carried out in this study. Further adherence to the protocol has been enhanced over time with reinforcement and increased familiarity with the protocol. Utilization, however, will most likely always be incomplete because of the time required for administration of antibiotics before delivery and unavoidable provider error.
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